N/A N=9 Bracing for Walking in Parkinson's Disease
Gait Disorders, Neurologic · Parkinson Disease
Primary: Change in Gait Capacity as Assessed b 6-Minute Walk Test — 235.7; 150.0 Feet
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=139 Study of Vitamin D in Untreated Metastatic Colorectal Cancer
Metastatic Colorectal Cancer
Primary: Median Progression-free Survival (PFS) — 11; 13 Months — p=0.07
N/A N=82 Role of Intravenous Versus Home Oral Antibiotics in Perforated Appendicitis
Perforated Appendicitis
Primary: Number of Participants With Postoperative Abscess — 5; 3 Participants — p=0.7188
N/A N=11 Treatments for Improving Mood in Depressed Teens-2
Depression
Primary: Acceptability — 9 Participants
Phase 2 N=1,053 A Study to Assess the Safety, Reactogenicity and Immune Response of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3844766A) in Older Adults
Respiratory Syncytial Virus Infections
Primary: Number of Subjects With Any Solicited Local Symptoms After First Vaccination Dose — 0; 1; 0; 0 Participants
N/A N=322 HIV Oral Testing Infographic Experiment
HIV/AIDS
Primary: HIV Self-testing Knowledge — 3.24; 3.79 score on a scale
N/A N=183 Empowered With Movement to Prevent Obesity and Weight Regain
Obesity · Weight Loss · Sedentary Lifestyle
Primary: Body Weight — 94.7; 91.6; 95.1 kg
Phase 2 N=72 A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19
COVID · Covid-19 · Coronavirus
Primary: Number of Subjects Who Experienced Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs — 4; 23; 22; 1 Participants
Phase 3 N=567 Gan & Lee Insulin Glargine Target Type (2) Evaluating Research
Diabetes Mellitus, Type 2
Primary: Treatment-induced Anti-Insulin Antibody (TI-AIA) is the Primary Endpoint — 54; 60 Percentage of subjects with TI-AIA
Phase 4 N=37 The Utility of IVCM to Assess Cellular Response and Efficacy of Long-term Topical Steroid Treatment in Patients With DED
Dry Eye Disease
Primary: IVCM for Density of Corneal Immune Dendritiform Cells — 9.47; 28.60 cells/mm^2
Phase 4 N=442 Supervised Asthma Medication in Schools (SAMS)
Childhood Asthma
Primary: The Primary Outcome Will be the Score on the Juniper Asthma Control Questionnaire (ACQ) — 54; 70; 74; 95 Participants
Phase 3 N=951 A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema
Diabetic Macular Edema
Primary: Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive Populations — 11.8; 10.8; 10.3; 11.7 ETDRS Letters — p=0.1718
Phase 3 N=940 A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE)
Diabetic Macular Edema
Primary: Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive Populations — 10.7; 11.6; 10.9; 10.6 ETDRS Letters — p=0.4699
N/A N=119 Lap-Band Surgery on Adolescents for Safety and Efficacy
Obesity · DM
Primary: Percentage of Excess Weight Loss (EWL) — 40.88 percentage of EWL
N/A N=699 Women Empowered to Live With Lupus Study
Lupus Erythematosus, Systemic
Primary: Communication With Physician - Stanford 3Q Scale Score — 3.1; 2.9; 3.3; 3.0 score on a scale